Pulmonary medicine utilizes clinical guidelines, randomized trials, and risk assessment tools for various respiratory conditions.
2
The 2026 GINA report updates asthma management based on recent literature reviewed by the GINA Science Committee.
3
The 2026 GOLD report revises COPD management criteria and includes updates on biologic therapy and emerging technologies.
4
The BOREAS trial demonstrated that dupilumab reduced exacerbations and improved lung function in COPD patients.
5
Updated ARDS guidelines conditionally recommend corticosteroids and ECMO for severe cases, while advising against prolonged lung recruitment maneuvers.